Ozempic, Wegovy Shortage Ends; New Drugs Emerge

The FDA has announced that Ozempic and Wegovy, GLP-1 drugs used for diabetes and weight loss, are no longer in short supply, impacting companies like Novo Nordisk and Hims & Hers. Novo Nordisk claims that selling compounded versions by Hims is illegal now that the shortage designation has been lifted, although Hims argues for exceptions due to clinical needs. New weight-loss drugs focusing on muscle preservation are in development from companies like Eli Lilly and Regeneron, aiming to reduce muscle loss, a concern with current treatments. These innovations could significantly impact the market, with potential annual sales reaching billions. Meanwhile, India is emerging as a significant market for weight-loss drugs as it faces a growing obesity crisis, attracting global pharmaceutical companies. Personal trainers emphasize the benefits of exercise during menopause for muscle and bone health, advocating for gradual increases in physical activity to improve overall well-being.